Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.43 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 5/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arildone SCHEMBL29807845 | 1.00 | MRGPRX4 (0.47) | MRGPRX4CYSLTR2CYSLTR1PPARAS1PR4 | |
| SCHEMBL11309550 | 1.00 | MRGPRX4 (0.47) | MRGPRX4CYSLTR2CYSLTR1PPARAS1PR4 | |
| SCHEMBL11546537 | 1.00 | MRGPRX4 (0.47) | MRGPRX4CYSLTR2CYSLTR1PPARAS1PR4 | |
| SCHEMBL11308216 | 0.99 | MRGPRX4 (0.48) | MRGPRX4CYSLTR2CYSLTR1PPARAS1PR4 | |
| SCHEMBL11359845 | 0.95 | MRGPRX4 (0.46) | MRGPRX4CYSLTR2CYSLTR1PPARAS1PR4 | |
| Arildone SCHEMBL28264892 | 0.94 | MRGPRX4 (0.43) | MRGPRX4CYSLTR2CYSLTR1PPARAS1PR4 | |
| SCHEMBL11614513 | 0.93 | PPARA (0.44) | PPARAMAPTL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL11544717 | 0.88 | PPARA (0.42) | PPARAMAPTL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL11455904 | 0.88 | NPC1 (0.43) | PPARAMAPTL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL11319008 | 0.88 | MRGPRX4 (0.49) | MRGPRX4CYSLTR2CYSLTR1PPARAS1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1459 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026043843-A1 | TETRAHYDROPYRIMIDINE (THP) IONIZABLE LIPIDS FOR EFFICIENT MRNA DELIVERY | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, (US) | 2026-02-26 | — | — | WO | claimed |
| WO-2024215771-A1 | SUBSTITUTED PHENYL ETHYNYL PYRIMIDINES AS POTENT INHIBITORS OF ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE (US) | 2024-10-17 | — | — | WO | claimed |
| EP-4262812-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | Southern Research Institute (US) | 2023-10-25 | — | — | EP | claimed |
| WO-2023122212-A2 | SUBSTITUTED PHENYL ETHYNYL PYRIDINE CARBOXAMIDES AS POTENT INHIBITORS OF SARS VIRUS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-06-29 | — | — | WO | claimed |
| EP-4125845-A1 | NOVEL 2-PYRIMIDONE ANALOGS AS POTENT ANTIVIRAL AGENTS AGAINST ALPHAVIRUSES | Southern Research Institute (US) | 2023-02-08 | — | — | EP | claimed |
| US-11534375-B2 | Solvent-free method of encapsulating a hydrophobic active | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-12-27 | — | — | US | claimed |
| EP-4021413-A1 | LIPOSOMAL TROPONOID COMPOUND FORMULATIONS | United States Government as Represented by The Department of Veterans Affairs (US) | 2022-07-06 | — | — | EP | claimed |
| WO-2022133323-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | SOUTHERN RESEARCH INSTITUTE (US) | 2022-06-23 | — | — | WO | claimed |
| WO-2021203048-A1 | NOVEL 2-PYRIMIDONE ANALOGS AS POTENT ANTIVIRAL AGENTS AGAINST ALPHAVIRUSES | SOUTHERN RESEARCH INSTITUTE (US) | 2021-10-07 | — | — | WO | claimed |
| US-20210299143-A1 | USE OF ANTAGONISTS TO THE NUCLEAR STEROID RECEPTOR TO INHIBIT CORONAVIRUSES | Spectral Analytics, Inc. (US) | 2021-09-30 | — | — | US | claimed |
| EP-1098641-A4 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | ST JUDE PHARMACEUTICALS INC (US) | 2003-08-27 | — | — | EP | claimed |
| US-6576636-B2 | Treating a noncentral nervous system by administering a covalent conjugate of a C8-26, unbranched, naturally occurring fatty acid and a drug, provided the drug is not an adenosine receptor agonist/antagonist; anticarcinogenics | PROTARGA, INC. | 2003-06-10 | — | — | US | claimed |
| WO-2003030934-A2 | CPG FORMULATIONS AND RELATED METHODS | MERIAL LIMITED (US) | 2003-04-17 | — | — | WO | claimed |
| US-6548055-B1 | Activation cell in immunology system | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-04-15 | — | — | US | claimed |
| EP-0776659-B1 | Delivery device for medicaments by the intravaginal route | AVENTIS PHARMA SA (FR) | 2002-04-10 | — | — | EP | claimed |
| WO-2001097749-A2 | THE USE OF SYNTHETIC, NON-HORMONAL 21-AMINOSTEROIDS AND THEREOF | KOTZE, GAVIN, SALOMON (ZA) | 2001-12-27 | — | — | WO | claimed |
| EP-1098641-A1 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | Texas Pharmaceuticals, Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000006143-A1 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | TEXAS PHARMACEUTICALS, INC. (US) | 2000-02-10 | — | — | WO | claimed |
| US-5788980-A | CONTAINING POLYSILOXANE RING MATRIX AND FATTY ESTER; CONTRACEPTIVE | ROUSSEL UCLAF (FR) | 1998-08-04 | — | — | US | claimed |
| WO-1998017282-A1 | METHODS OF USING SUCROSE OCTASULFATE TO TREAT OR PREVENT ENVELOPED VIRUS INFECTION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1998-04-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299143-A1 | USE OF ANTAGONISTS TO THE NUCLEAR STEROID RECEPTOR TO INHIBIT CORONAVIRUSES | NCOA1, NCOA2, NCOA3 | MRGPRX4 906/4885CYSLTR2 673/4885CYSLTR1 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.